Stocks and Investing Stocks and Investing
Tue, October 31, 2023

Gregory Renza Maintained (VRDN) at Buy with Decreased Target to $35 on, Oct 31st, 2023


Published on 2024-10-28 07:12:39 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Decreased Target from $44 to $35 on, Oct 31st, 2023.

Gregory has made no other calls on VRDN in the last 4 months.



There are 5 other peers that have a rating on VRDN. Out of the 5 peers that are also analyzing VRDN, 0 agree with Gregory's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Gregory


  • Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, October 30th, 2023
  • Alex Thompson of "Stifel" Reiterated at Strong Buy and Held Target at $40 on, Wednesday, September 13th, 2023
  • Douglas Tsao of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $37 on, Thursday, August 10th, 2023
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $42 on, Wednesday, August 9th, 2023
  • Leland Gershell of "Oppenheimer" Maintained at Buy with Decreased Target to $35 on, Wednesday, August 9th, 2023

Contributing Sources